ImmunityBio (IBRX) Capital Expenditures (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Capital Expenditures data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 1673.2% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 22.29% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.1 million, up from $792000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for IBRX reached as high as $43.4 million in Q2 2022 and fell as low as -$12.7 million in Q4 2023.
• Historically, Capital Expenditures has averaged $5.0 million across 5 years, with a median of $1.2 million in 2024.
• Across the five-year window, Capital Expenditures jumped 63919.12% in 2022 and plunged 191.98% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $18.9 million in 2022, then tumbled by 166.91% to -$12.7 million in 2023, then soared by 71.03% to -$3.7 million in 2024, then surged by 121.59% to $792000.0 in 2025, then soared by 32.83% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $1.1 million in Q1 2026, $792000.0 in Q4 2025, and -$1.6 million in Q3 2025.